A landmark Phase III trial published in The Lancet has demonstrated a five-year overall survival rate of 90.9% for oropharyngeal cancer patients treated with proton therapy, compared with 81% for those receiving traditional radiation. The study, led by the University of Texas MD Anderson Cancer Center, enrolled 440 patients across 21 proton centers in the U.S. and provides some of the clearest evidence yet that proton therapy's ability to spare healthy tissue translates into meaningful survival benefits.
For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The core limitation persisted: photon beams pass through the body, leaving an exit dose of radiation in tissue beyond the tumor. The question oncologists repeatedly returned to was not whether this collateral exposure mattered, but how much it mattered over a patient’s lifetime. The December 2025 study offers compelling answers, and the findings are beginning to influence how cancer treatment infrastructure is being planned.
Proton therapy’s ability to stop at a precise depth within the body reduces radiation exposure to surrounding healthy tissue, a clinical advantage driving new facility investments across the U.S., including a proton center scheduled to open this summer in Boca Raton, Florida. The results from the MD Anderson trial are expected to accelerate such investments, as the survival gap—nearly 10 percentage points—changes the conversation around treatment standards.
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) has positioned itself at the intersection of this shift. In November 2025, the company acquired Liora Technologies Europe Ltd., now a subsidiary of LIXTE and developer of the electronically controlled LiGHT proton therapy platform. This acquisition extends LIXTE’s reach beyond its traditional pharmaceutical focus into advanced radiation oncology, aligning with the growing evidence supporting proton therapy.
Forward-looking statements in this article involve risks and uncertainties, including those detailed in LIXTE's SEC filings. The full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.
